Ono granted Merck's Merck Serono S.A. division exclusive rights outside of Japan, Korea and Taiwan to develop and commercialize multiple sclerosis (MS) compound ONO-4641

Ono Pharmaceutical Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Merck KGaA

Germany / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated